PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Recent News

  • PreveCeutical Announces Successful Completion of its Sol-gel Program

    Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the successful completion of its Cannabinoid Sol-Gel Delivery Program (the "Sol-gel Program").The Sol-gel Program developed and evaluated translatable formulations for the central nervous system (CNS) delivery...

    2020-06-03 7:00 AM ET
  • PreveCeutical Applies for Viral Prevention Program Funding

    Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), is pleased to inform that, in connection with its previously announced extension to its successful cannabis sol-gel program (the "Program Extension") to address the COVID-19 pandemic (News Release...

    2020-06-01 8:52 AM ET
  • PreveCeutical Announces Debt Settlement and Conversion of Debt

    Vancouver, British Columbia--(Newsfile Corp. - May 22, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical")  announces that it has issued 95,600,253 common shares without par value in its capital (each, a "Share") to various arm's length creditors of the Company at a deemed...

    2020-05-22 5:02 PM ET
  • PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel

    Vancouver, British Columbia--(Newsfile Corp. - May 4, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it is working on an extension to its successful cannabis sol-gel program to address the COVID-19 pandemic (the "Program Extension"). The Company is not making...

    2020-05-04 1:37 PM ET
  • PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller

    Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce an update to its Non-Addictive Analgesic (dynorphin pain peptide) Program.Following the identification and shortlisting of a panel of peptides showing promising cell-based activity and extended stability...

    2020-04-29 8:00 AM ET
  • PreveCeutical Announces Patent Cooperation Treaty ("PCT") Application

    Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the two Australian provisional applications entitled, "A Cyclic Peptide", which were filed last year by The University of Queensland, Australia ("UQ") have...

    2020-02-24 9:00 AM ET
  • PreveCeutical Retains Patent Legal Team

    Vancouver, British Columbia--(Newsfile Corp. - January 23, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") has retained Griffith Hack as their patent attorneys. Following the successful completion of our novel designed peptides derived from Caribbean blue scorpion venom and with our two...

    2020-01-23 9:00 AM ET
  • PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

    Vancouver, British Columbia--(Newsfile Corp. - January 14, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide a further update on its dual gene therapy research program (the "Dual Gene Therapy Program"), an important and fundamental aspect of which involves...

    2020-01-14 9:00 AM ET